



(11) **EP 2 824 108 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
12.07.2017 Bulletin 2017/28

(45) Date of publication and mention
of the grant of the patent:
19.04.2017 Bulletin 2017/16

(21) Application number: **13847102.4**

(22) Date of filing: **06.03.2013**

(51) Int Cl.:
C07H 15/252^(2006.01) C07H 19/044^(2006.01)
A61K 31/7056^(2006.01) A61P 35/00^(2006.01)

(86) International application number:
PCT/CN2013/000233

(87) International publication number:
WO 2014/059740 (24.04.2014 Gazette 2014/17)

(54) **TETRACYCLIC ANTHRAQUINONE DERIVATIVES**

TETRACYCLISCHE ANTHRACHINONDERIVATE
DÉRIVÉS D'ANTHRAQUINONE TÉTRACYCLIQUE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **06.03.2012 CN 201210055298**

(43) Date of publication of application:
14.01.2015 Bulletin 2015/03

(73) Proprietor: **TIANJIN HEMAY ONCOLOGY**
PHARMACEUTICAL CO., LTD.
Xiqing Economic-Technological Development
Area
Tianjin 300385 (CN)

(72) Inventors:
• **ZHANG, Hesheng**
Tianjin 300457 (CN)
• **HUO, Aihong**
Tianjin 300457 (CN)
• **LI, Zhenzhong**
Tianjin 300457 (CN)

(74) Representative: **Smith, Matthew et al**
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE (GB)

(56) References cited:
WO-A1-2009/099741 CN-A- 101 555 264

- **JÖRG B. ENGEL ET AL: "Targeted Therapy of Breast and Gynecological Cancers with Cytotoxic Analogues of Peptide Hormones", MOLECULAR PHARMACEUTICS, vol. 4, no. 5, 1 October 2007 (2007-10-01), pages 652-658, XP055203726, ISSN: 1543-8384, DOI: 10.1021/mp0700514**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

EP 2 824 108 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).